|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/09/21 Marinus Pharmaceuticals Inc. 10-K 12/31/20 65:7.6M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.27M
2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 41K
6: EX-10.22 Material Contract HTML 67K
3: EX-10.3 Material Contract HTML 78K
4: EX-10.4 Material Contract HTML 64K
5: EX-10.9 Material Contract HTML 72K
7: EX-21 Subsidiaries List HTML 17K
8: EX-23.1 Consent of Expert or Counsel HTML 21K
9: EX-23.2 Consent of Expert or Counsel HTML 18K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
19: R1 Document and Entity Information HTML 82K
20: R2 Consolidated Balance Sheets HTML 89K
21: R3 Consolidated Balance Sheets (Parenthetical) HTML 50K
22: R4 Consolidated Statements of Operations and HTML 57K
Comprehensive Loss
23: R5 Consolidated Statements of Stockholders' Equity HTML 89K
24: R6 Consolidated Statements of Stockholders' Equity HTML 25K
(Parenthetical)
25: R7 Consolidated Statements of Cash Flows HTML 81K
26: R8 Organization and Description of the Business HTML 32K
27: R9 Summary of Significant Accounting Policies HTML 66K
28: R10 Fair Value Measurements HTML 65K
29: R11 Property and Equipment HTML 37K
30: R12 Accrued Expenses HTML 36K
31: R13 Leases HTML 43K
32: R14 Investments HTML 20K
33: R15 Stockholders' Equity HTML 146K
34: R16 Convertible Preferred Stock HTML 24K
35: R17 Commitments and Contingencies HTML 26K
36: R18 Income Taxes HTML 90K
37: R19 Summary of Significant Accounting Policies HTML 110K
(Policies)
38: R20 Summary of Significant Accounting Policies HTML 50K
(Tables)
39: R21 Fair Value Measurements (Tables) HTML 61K
40: R22 Property and Equipment (Tables) HTML 36K
41: R23 Accrued Expenses (Tables) HTML 35K
42: R24 Leases (Tables) HTML 37K
43: R25 Stockholders' Equity (Tables) HTML 142K
44: R26 Income Taxes (Tables) HTML 84K
45: R27 Organization and Description of the Business HTML 84K
(Details)
46: R28 Summary of Significant Accounting Policies - HTML 31K
Property and Equipment (Details)
47: R29 Summary of Significant Accounting Policies - Loss HTML 49K
Per Share of Common Stock (Details)
48: R30 Summary of Significant Accounting Policies - HTML 20K
Segment Information (Details)
49: R31 Fair Value Measurements (Details) HTML 33K
50: R32 Property and Equipment (Details) HTML 35K
51: R33 Accrued Expenses (Details) HTML 32K
52: R34 Leases (Details) HTML 67K
53: R35 Leases - Maturities (Details) HTML 43K
54: R36 Stockholders' Equity - Incentive Plans (Details) HTML 38K
55: R37 Stockholders' Equity - Stock Options and HTML 161K
Restricted Stock (Details)
56: R38 Stockholders' Equity - Equity Distribution HTML 40K
Agreement (Details)
57: R39 Stockholders' Equity - Public Offering (Details) HTML 38K
58: R40 Convertible Preferred Stock (Details) HTML 57K
59: R41 Commitments and Contingencies - Employee Benefit HTML 28K
Plan and License Agreements (Details)
60: R42 Commitments and Contingencies - Employee and HTML 31K
Severance Arrangements (Details)
61: R43 Income Taxes (Details) HTML 94K
63: XML IDEA XML File -- Filing Summary XML 103K
18: XML XBRL Instance -- mrns-20201231x10k_htm XML 1.40M
62: EXCEL IDEA Workbook of Financial Reports XLSX 73K
14: EX-101.CAL XBRL Calculations -- mrns-20201231_cal XML 138K
15: EX-101.DEF XBRL Definitions -- mrns-20201231_def XML 498K
16: EX-101.LAB XBRL Labels -- mrns-20201231_lab XML 1.11M
17: EX-101.PRE XBRL Presentations -- mrns-20201231_pre XML 789K
13: EX-101.SCH XBRL Schema -- mrns-20201231 XSD 124K
64: JSON XBRL Instance as JSON Data -- MetaLinks 280± 438K
65: ZIP XBRL Zipped Folder -- 0001558370-21-002646-xbrl Zip 406K
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| 1. | Registration Statement (Form S-3 No. 333-239780) of Marinus Pharmaceuticals, Inc.; |
| 2. | Registration Statement (Form S-3 No. 333-237903) of Marinus Pharmaceuticals, Inc.; |
| 3. | Registration Statement (Form S-8 No. 333-239785) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and Individual Nonqualified Stock Option Awards; |
| 4. | Registration Statement (Form S-8 No. 333-233131) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and Individual Nonqualified Stock Option Awards; |
| 5. | Registration Statement (Form S-8 No. 333-219613) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan; and |
| 6. | Registration Statement (Form S-8 No. 333-200701) pertaining to the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan; |
of our report dated March 9, 2021, with respect to the financial statements of Marinus Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Marinus Pharmaceuticals, Inc. for the year ended December 31, 2020.
Philadelphia, PA
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/9/21 | 4, 8-K | ||
| For Period end: | 12/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/24 Marinus Pharmaceuticals, Inc. 10-K 12/31/23 79:10M Toppan Merrill Bridge/FA 3/09/23 Marinus Pharmaceuticals, Inc. 10-K 12/31/22 73:10M Toppan Merrill Bridge/FA 3/24/22 Marinus Pharmaceuticals, Inc. 10-K 12/31/21 71:8.5M Toppan Merrill Bridge/FA 8/10/21 Marinus Pharmaceuticals, Inc. S-8 8/10/21 5:200K Toppan Merrill/FA |